Abstract
The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Current Drug Therapy
Title:Complications of Anti-Vascular Endothelial Growth Factor Drugs
Volume: 7 Issue: 2
Author(s): Michael Tolentino
Affiliation:
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Abstract: The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Export Options
About this article
Cite this article as:
Tolentino Michael, Complications of Anti-Vascular Endothelial Growth Factor Drugs, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800675959
DOI https://dx.doi.org/10.2174/157488512800675959 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Echocardiogram versus Cardiac Magnetic Resonance Imaging for the Diagnosis of Non-compaction Cardiomyopathy – A Case Report
New Emirates Medical Journal Polyphenols: Novel Signaling Pathways
Current Pharmaceutical Design Arterial Stiffness, Pulse Wave Analyses: What Can’t Blood Pressure Tell you in Chronic Kidney Disease
Current Hypertension Reviews Trace Extraction of Metoprolol from Plasma, Urine and EBC Samples Using Modified Magnetic Nanoparticles Followed by Spectrofluorimetric Determination for Drug Monitoring Purposes
Current Pharmaceutical Analysis Dietary Patterns and Cognitive Decline: key features for prevention
Current Pharmaceutical Design Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Effects of Hypertension, Diabetes Mellitus, Obesity and Other Factors on Kidney Haemodynamics
Current Vascular Pharmacology Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Current Problems with Non-Specific COX Inhibitors
Current Pharmaceutical Design Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Insulin Resistance in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Job Stress and Blood Pressure: A Critical Appraisal of Reported Studies
Current Hypertension Reviews Defining the Molecular Nexus of Cancer, Type 2 Diabetes and Cardiovascular Disease
Current Molecular Medicine The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Rare Genetic Diseases with Human Lean and/or Starvation Phenotype Open New Avenues for Obesity and Type II Diabetes Treatment
Current Pharmaceutical Biotechnology Systemic Inflammation Induces Endothelial Dysfunction in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Latest Advances in Breast Sonography
Recent Patents on Medical Imaging